Project Grant R44NS095481

The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a sub-awardee....

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

Federal Project Grant Award Summary Aquinnah Pharmaceuticals, Inc. received a $1,499,212 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective June 15, 2025, with completion targeted for May 31, 2027. The award supports the development of a novel oral, brain-penetrant therapeutic candidate designed to treat amyotrophic lateral sclerosis...

The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...

This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the dysfunction of neuroimmune-related processes in animal models of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) associated with TAR DNA-binding protein 43 (TDP-43). The $251,250 award, effective from Apr 1, 2025 to Mar 31,...

The U.S. Defense Health Agency awarded a $1,979,313 Project Grant to Sachi Bioworks, Inc., a small disadvantaged business in Erie, Colorado, to develop a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). This award is part of the agency's Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. Sachi Bioworks specializes...

Federal Grant Award Summary The University of Massachusetts Medical School received a $460,625 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2025, through May 31, 2027. The award funds investigator-initiated research to elucidate the role of TDP-43 (TAR-DNA-binding protein-43) citrullination in amyotrophic lateral sclerosis (ALS)...

Acurastem Inc. received a $839,898.40 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an UNC13A antisense oligonucleotide treatment for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) from June 1, 2023 to May 31, 2025. The grant funding will support Acurastem's efforts to advance a novel gene therapy targeting UNC13A, a gene implicated in ALS and FTD, using antisense oligonucleotide...